Search

Your search keyword '"Fukihara, Jun"' showing total 35 results
Start Over Author "Fukihara, Jun"
35 results on '"Fukihara, Jun"'

4. Idiopathic Pulmonary Fibrosis Incidentally Detected by CT Scan as Interstitial Lung Abnormalities

Author

Bando, Tomohiro, primary, Takei, Reoto, additional, Fukihara, Jun, additional, Sasano, Hajime, additional, Yamano, Yasuhiko, additional, Yokoyama, Toshiki, additional, Matsuda, Toshiaki, additional, Kataoka, Kensuke, additional, Kimura, Tomoki, additional, Fukuoka, Junya, additional, Hatabu, Hiroto, additional, Johkoh, Takeshi, additional, and Kondoh, Yasuhiro, additional

Published
2024
Full Text
View/download PDF

6. Mild elevation of pulmonary vascular resistance predicts mortality regardless of mean pulmonary artery pressure in mild interstitial lung disease

Author

Sato, Tomonori, primary, Furukawa, Taiki, additional, Teramachi, Ryo, additional, Fukihara, Jun, additional, Yamano, Yasuhiko, additional, Yokoyama, Toshiki, additional, Matsuda, Toshiaki, additional, Kataoka, Kensuke, additional, Kimura, Tomoki, additional, Sakamoto, Koji, additional, Ishii, Makoto, additional, and Kondoh, Yasuhiro, additional

Published
2024
Full Text
View/download PDF

10. Preclinical idiopathic pulmonary fibrosis (IPF): a retrospective cohort study

Author

Bando, Tomohiro, primary, Takei, Reoto, additional, Fukihara, Jun, additional, Sasano, Hajime, additional, Yamano, Yasuhiko, additional, Yokoyama, Toshiki, additional, Matsuda, Toshiaki, additional, Kataoka, Kensuke, additional, Kimura, Tomoki, additional, Hatabu, Hiroto, additional, Fukuoka, Junya, additional, Johkoh, Takeshi, additional, and Kondoh, Yasuhiro, additional

Published
2023
Full Text
View/download PDF

11. Early intervention of antifibrotics along with anti-inflammatory treatment in rapidly progressive interstitial lung disease (RP-ILD) with anti-MDA5 antibody-positive dermatomyositis (MDA5-DM)

Author

Bando, Tomohiro, primary, Yamano, Yasuhiko, additional, Takei, Reoto, additional, Sasano, Hajime, additional, Fukihara, Jun, additional, Yokoyama, Toshiki, additional, Matsuda, Toshiaki, additional, Kataoka, Kensuke, additional, Kimura, Tomoki, additional, Johkoh, Takeshi, additional, Fukuoka, Junya, additional, and Kondoh, Yasuhiro, additional

Published
2023
Full Text
View/download PDF

12. Idiopathic Pulmonary Fibrosis Incidentally Detected by Computed Tomography Scan as Interstitial Lung Abnormalities.

Author

Bando, Tomohiro, Takei, Reoto, Fukihara, Jun, Sasano, Hajime, Yamano, Yasuhiko, Yokoyama, Toshiki, Matsuda, Toshiaki, Kataoka, Kensuke, Kimura, Tomoki, Fukuoka, Junya, Hatabu, Hiroto, Johkoh, Takeshi, and Kondoh, Yasuhiro

Subjects
LUNGS, IDIOPATHIC pulmonary fibrosis, COMPUTED tomography, MEDICAL personnel
Abstract

The article investigates incidentally detected interstitial lung abnormalities (ILAs) in preclinical idiopathic pulmonary fibrosis (IPF), comparing them with clinically diagnosed IPF. It highlights the significance of ILA detection and suggests early evaluation and referral for possible IPF diagnosis.

Published
2024
Full Text
View/download PDF

14. Changes in patient-reported outcomes in patients with non-idiopathic pulmonary fibrosis fibrotic interstitial lung disease and progressive pulmonary fibrosis

Author

Takei, Reoto, primary, Matsuda, Toshiaki, additional, Fukihara, Jun, additional, Sasano, Hajime, additional, Yamano, Yasuhiko, additional, Yokoyama, Toshiki, additional, Kataoka, Kensuke, additional, Kimura, Tomoki, additional, Suzuki, Atsushi, additional, Furukawa, Taiki, additional, Fukuoka, Junya, additional, Johkoh, Takeshi, additional, and Kondoh, Yasuhiro, additional

Published
2023
Full Text
View/download PDF

15. Real-World Experience of the Comparative Effectiveness and Safety of Molnupiravir and Nirmatrelvir/Ritonavir in High-Risk Patients with COVID-19 in a Community Setting

Author

Mutoh, Yoshikazu, primary, Umemura, Takumi, additional, Nishikawa, Takeshi, additional, Kondo, Kaho, additional, Nishina, Yuta, additional, Soejima, Kazuaki, additional, Noguchi, Yoichiro, additional, Bando, Tomohiro, additional, Ota, Sho, additional, Shimahara, Tatsuki, additional, Hirota, Shuko, additional, Hagimoto, Satoshi, additional, Takei, Reoto, additional, Fukihara, Jun, additional, Sasano, Hajime, additional, Yamano, Yasuhiko, additional, Yokoyama, Toshiki, additional, Kataoka, Kensuke, additional, Matsuda, Toshiaki, additional, Kimura, Tomoki, additional, Ichihara, Toshihiko, additional, and Kondoh, Yasuhiro, additional

Published
2023
Full Text
View/download PDF

16. BMP3b Is a Novel Antifibrotic Molecule Regulated by Meflin in Lung Fibroblasts

Author

Suzuki, Atsushi, primary, Sakamoto, Koji, additional, Nakahara, Yoshio, additional, Enomoto, Atsushi, additional, Hino, Jun, additional, Ando, Akira, additional, Inoue, Masahide, additional, Shiraki, Yukihiro, additional, Omote, Norihito, additional, Kusaka, Masahiro, additional, Fukihara, Jun, additional, and Hashimoto, Naozumi, additional

Published
2022
Full Text
View/download PDF

18. Overexpression of bone morphogenetic protein receptor type 2 suppresses transforming growth factor ��-induced profibrotic responses in lung fibroblasts

Author

Fukihara, Jun, Maiolo, Suzanne, Kovac, Jessica, Sakamoto, Koji, Wakahara, Keiko, Hashimoto, Naozumi, and Reynolds, Paul N.

Subjects
respiratory system, respiratory tract diseases
Abstract

Purpose of the study: Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a poor prognosis. As the efficacy of currently available antifibrotics is limited, development of new therapies is warranted. Transforming growth factor (TGF)-�� plays a central role in the pathogenesis of IPF through mechanisms such as promoting the production of extracellular matrix by fibroblasts. Conversely, bone morphogenetic proteins (BMPs) are known to be antifibrotic and may counterbalance TGF-�� signaling via BMP receptor type 2 (BMPR2). However, little is known about the expression status of BMPR2 and its function in pulmonary fibrosis, and manipulation of BMPR2 expression has never been attempted. In this study, we aimed at evaluating the effectiveness of BMPR2 upregulation for modulating the imbalance of the TGF-��/BMP axis and reduce the profibrotic changes in lung fibroblasts. We investigated BMPR2 expression in pulmonary fibrosis and TGF-��/BMP signaling in lung fibroblasts. Then we evaluated the impact of BMPR2 upregulation using adenoviral transduction on TGF-��-induced Smad2/3 phosphorylation and fibronectin production in lung fibroblasts. BMPR2 was distributed in airway epithelium and alveolar walls in rat lungs. BMPR2 expression was decreased in fibrotic lesions in the lungs of rats with bleomycin-induced pulmonary fibrosis and in human lung fibroblasts (HLFs) stimulated with TGF-��. Although Smad2/3 phosphorylation and fibronectin production were not suppressed solely by BMPs, phosphorylated Smad2/3 was decreased in BMPR2-transduced cells even without BMP stimulation. Fibronectin was decreased only when BMPR2-transduced HLFs were stimulated with BMP7 (but not BMP4). Similar results were also observed in IPF patient HLFs and rat lung fibroblasts. BMPR2 expression was reduced in fibrotic lungs and lung fibroblasts stimulated with TGF-��. BMPR2 transduction to lung fibroblasts reduced Smad2/3 phosphorylation, and reduced fibronectin production when treated with BMP7. Upregulation of BMPR2 may be a possible strategy for treating pulmonary fibrosis.

Published
2022
Full Text
View/download PDF

21. Reply to “Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non–Small-Cell Lung Cancer Who Received Programmed Death-1 Inhibitors”

Author

Fukihara, Jun, primary, Sakamoto, Koji, additional, Koyama, Junji, additional, Ito, Takayasu, additional, Iwano, Shingo, additional, Morise, Masahiro, additional, Ogawa, Masahiro, additional, Kondoh, Yasuhiro, additional, Kimura, Tomoki, additional, Hashimoto, Naozumi, additional, and Hasegawa, Yoshinori, additional

Published
2020
Full Text
View/download PDF

22. Probable usual interstitial pneumonia pattern on chest CT: is it sufficient for a diagnosis of idiopathic pulmonary fibrosis?

Author

Fukihara, Jun, primary, Kondoh, Yasuhiro, additional, Brown, Kevin K., additional, Kimura, Tomoki, additional, Kataoka, Kensuke, additional, Matsuda, Toshiaki, additional, Yamano, Yasuhiko, additional, Suzuki, Atsushi, additional, Furukawa, Taiki, additional, Sumikawa, Hiromitsu, additional, Takahashi, Osamu, additional, Johkoh, Takeshi, additional, Tanaka, Tomonori, additional, Fukuoka, Junya, additional, Hashimoto, Naozumi, additional, and Hasegawa, Yoshinori, additional

Published
2020
Full Text
View/download PDF

23. Immune checkpoint inhibitor for advanced or recurrent non-small cell lung cancer patients with poor performance status

Author

Koyama, Junji, primary, Kimura, Tomoki, additional, Oi, Hajime, additional, Yamano, Yasuhiko, additional, Yokoyama, Toshiki, additional, Matsuda, Toshiaki, additional, Kataoka, Kensuke, additional, Matsuzawa, Reiko, additional, Fukihara, Jun, additional, Sakamoto, Koji, additional, Morise, Masahiro, additional, Hashimoto, Naozumi, additional, Kondoh, Yasuhiro, additional, and Hasegawa, Yoshinori, additional

Published
2019
Full Text
View/download PDF

25. Acute exacerbations of fibrotic interstitial lung diseases

Author

Suzuki, Atsushi, primary, Kondoh, Yasuhiro, additional, Brown, Kevin K., additional, Johkoh, Takeshi, additional, Kataoka, Kensuke, additional, Fukuoka, Junya, additional, Kimura, Tomoki, additional, Matsuda, Toshiaki, additional, Yokoyama, Toshiki, additional, Fukihara, Jun, additional, Ando, Masahiko, additional, Tanaka, Tomonori, additional, Hashimoto, Naozumi, additional, Sakamoto, Koji, additional, and Hasegawa, Yoshinori, additional

Published
2019
Full Text
View/download PDF

26. Responsiveness and minimal clinically important difference of the COPD Assessment Test in fibrotic interstitial lung disease

Author

Matsuda, Toshiaki, Kondoh, Yasuhiro, Takei, Reoto, Sasano, Hajime, Fukihara, Jun, Yamano, Yasuhiko, Yokoyama, Toshiki, Kataoka, Kensuke, Watanabe, Fumiko, and Kimura, Tomoki

Abstract

Patients with fibrotic interstitial lung disease (FILD) have impaired health status. The simple questionnaire in the COPD assessment test (CAT) has been validated for idiopathic pulmonary fibrosis (IPF) and connective tissue disease-related interstitial lung disease (CTD-ILD), but no or limited data exist for patients with FILD as a whole. The aim of this study was to evaluate the reliability, repeatability and responsiveness of the CAT, and estimate the minimal clinically important difference (MCID) in patients with FILD.

Published
2024
Full Text
View/download PDF

27. Acute exacerbations of fibrotic interstitial lung diseases.

Author

Suzuki, Atsushi, Kondoh, Yasuhiro, Brown, Kevin K., Johkoh, Takeshi, Kataoka, Kensuke, Fukuoka, Junya, Kimura, Tomoki, Matsuda, Toshiaki, Yokoyama, Toshiki, Fukihara, Jun, Ando, Masahiko, Tanaka, Tomonori, Hashimoto, Naozumi, Sakamoto, Koji, and Hasegawa, Yoshinori

Subjects
IDIOPATHIC pulmonary fibrosis, HYPERSENSITIVITY pneumonitis, PULMONARY fibrosis, INTERSTITIAL lung diseases, IDIOPATHIC interstitial pneumonias, LOG-rank test, CONNECTIVE tissues
Abstract

Background and objective: Acute exacerbation (AE) is a severe complication of idiopathic pulmonary fibrosis (AE‐IPF). In 2016, an international working group revised its definition and diagnostic criteria; however, few studies have assessed the frequency and prognosis of AE in patients with other fibrotic interstitial lung diseases (FILD). Methods: We used data from 1019 consecutive interstitial lung disease (ILD) patients initially evaluated between January 2008 and July 2015. All subject diagnoses were made by multidisciplinary discussion in December 2018. ILD was categorized as IPF (n = 462) and other FILD which included non‐specific interstitial pneumonia (n = 22), chronic hypersensitivity pneumonitis (n = 29), connective tissue disease‐associated ILD (n = 205) and unclassifiable ILD (n = 209). Using the 2016 definition of AE‐IPF, we identified all subjects with an AE. Results: During the observational period, 193 patients experienced a first AE (AE‐FILD n = 69, AE‐IPF n = 124). The time to first AE was significantly longer in FILD than IPF (log‐rank test, P < 0.001). After adjusting for potentially influential confounders, FILD remained a significant predictor of longer time to first AE compared with IPF (hazard ratio: 0.453; 95% CI: 0.317–0.647, P = 0.006). In a multivariate Cox proportional analysis, baseline disease severity was closely associated with the incidence of AE‐ILD. Even after adjustment for other clinical variables, AE had a negative impact on overall survival. AE‐FILD and AE‐IPF showed similar poor short‐term outcomes. Conclusion: All forms of ILD are at risk of AE and have a similar outcome to AE‐IPF. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

30. Hemosiderin-laden macrophages are an independent factor correlated with pulmonary vascular resistance in idiopathic pulmonary fibrosis: a case control study

Author

Fukihara, Jun, primary, Taniguchi, Hiroyuki, additional, Ando, Masahiko, additional, Kondoh, Yasuhiro, additional, Kimura, Tomoki, additional, Kataoka, Kensuke, additional, Furukawa, Taiki, additional, Johkoh, Takeshi, additional, Fukuoka, Junya, additional, Sakamoto, Koji, additional, and Hasegawa, Yoshinori, additional

Published
2017
Full Text
View/download PDF

33. Hemosiderin-laden macrophages are an independent factor correlated with pulmonary vascular resistance in idiopathic pulmonary fibrosis: a case control study.

Author

Jun Fukihara, Hiroyuki Taniguchi, Masahiko Ando, Yasuhiro Kondoh, Tomoki Kimura, Kensuke Kataoka, Taiki Furukawa, Takeshi Johkoh, Junya Fukuoka, Koji Sakamoto, Yoshinori Hasegawa, Fukihara, Jun, Taniguchi, Hiroyuki, Ando, Masahiko, Kondoh, Yasuhiro, Kimura, Tomoki, Kataoka, Kensuke, Furukawa, Taiki, Johkoh, Takeshi, and Fukuoka, Junya

Subjects
HEMOSIDERIN, MACROPHAGES, PULMONARY hypertension, BRONCHOALVEOLAR lavage, HEMODYNAMICS, HYPERTENSION risk factors, ARTERIES, BLOOD pressure, BODY fluids, CARDIAC catheterization, ECHOCARDIOGRAPHY, LUNGS, VASCULAR resistance, METALLOPROTEINS, MULTIVARIATE analysis, REGRESSION analysis, PULMONARY function tests, RETROSPECTIVE studies, SEVERITY of illness index, CASE-control method, IDIOPATHIC pulmonary fibrosis, THERAPEUTICS
Abstract

Background: Increases in hemosiderin-laden macrophages (HLM) are reported to be observed in idiopathic pulmonary fibrosis (IPF). According to a recent study, significant correlation between hemosiderin deposition in the lung tissue of IPF and pulmonary hypertension evaluated by echocardiography has been suspected. In this study, we aimed to evaluate whether HLM in bronchoalveolar lavage fluid (BALF) is a factor correlated with pulmonary hemodynamic parameters evaluated by right heart catheterization in patients with IPF.Methods: Initial data from 103 consecutive patients with IPF who underwent surgical lung biopsy between November 2007 and March 2014 were retrospectively analyzed. The "HLM score" of BALF was established by dividing the number of Perls' Prussian blue stain positive macrophages by the total number of macrophages counted.Results: BALF showed an elevated HLM score (38.2%). Right heart catheterization revealed mean pulmonary arterial pressure (mPAP) of 16.3 mmHg and pulmonary vascular resistance (PVR) of 1.55 Wood units. HLM score was positively correlated with mPAP (ρ = 0.204; p = 0.038) and PVR (ρ = 0.349, p < 0.001). In multivariate analysis, 6-min walk distance (standardized partial regression coefficient [β], -0.391; p < 0.001), minimum oxygen saturation during 6-min walk distance (β, -0.294; p = 0.001) and HLM score (β, 0.265; p = 0.002) were independently correlated with PVR.Conclusions: HLM score in BALF is an independent factor correlated with PVR in patients with IPF. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

35. Effectiveness of remdesivir-based therapy for moderate COVID-19: comparison of Omicron and other variant phases.

Author

Suzuki A, Fukumitsu K, Fukihara J, Katano T, Kako H, Maeda Y, Ishii M, Niimi A, Imaizumi K, and Yamaguchi E

Subjects
Humans, SARS-CoV-2, Retrospective Studies, COVID-19 Drug Treatment, Oxygen, COVID-19, Adenosine Monophosphate analogs & derivatives, Alanine analogs & derivatives
Abstract

Remdesivir is an antiviral drug for the treatment of coronavirus disease 2019 (COVID-19), and the sustained antiviral activity against Omicron variants of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has been reported. In this single-center retrospective study, we first compared the clinical effectiveness of remdesivir-based therapy between Omicron and other variant phases of moderate COVID-19 in a real-world setting. Between Dec 2020 and July 2022, a total of 406 patients with COVID-19 pneumonia were treated with remdesivir-based therapy on admission. The oxygen deterioration rate after initiation of treatment significantly decreased in the Omicron variant phase compared to the alpha and delta variant phases. In an adjusted multivariate Cox proportional hazards model, Omicron variant phase was significantly associated with delayed oxygen deterioration and early recovery from hypoxia. These favorable outcomes during the Omicron variant phase, compared to previous variant phases, might be due to the attenuation and the popularization of vaccination.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results